AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03817229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated digital reminders
Description: reminders from electronic monitors based on texts or lights/chimes
Study NCT03817229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-solving mHealth module
Description: mhealht problem solving module with 2 telehealth sessions with a therapist
Study NCT03817229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Adherence Feedback Report
Description: Individual Adherence Feedback reports sent to parents weekly
Study NCT03416751 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbial Transplant
Description: Fecal transplant from a donor in the OpenBiome Registry
Study NCT03416751 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo enemas
Study NCT03711318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Description: 3 week treatment with buprenorphine/naloxone
Study NCT01373242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liquid peanut extract (Peanut SLIT)
Description: Liquid peanut extract will be administered under the tongue
Study NCT01781364 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Fitness Training, Posit Science SF
Description: Computer aided cognitive training based on principles of neuroplasticity
Study NCT05840640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Therapy
Description: Standard medical therapy involves primary treatment with normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.
Study NCT05840640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Therapy
Description: Standard medical therapy involves primary treatment with normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.
Study NCT05840640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: standard medical therapy plus G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days
Study NCT05840640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF and NAC
Description: Standard Medical Therapy plus G-CSF with intravenous NAC (day 1: NAC at 150, 50, and 100 mg/kg in 250, 500, and 1000 ml of 5% glucose solution over 30 minutes, 4 hours, and 16 hours, respectively; days 2 through 5: 100 mg/kg/day in 1000 ml of 5% glucose solution followed by oral NAC from days 6 to 28)
Study NCT04974983 — intervention group
Intervention type: OTHER
Intervention: Observation of neurological deficits
Description: Observation of neurological deficits
Study NCT04850482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MyJourney
Description: MyJourney is an online self-help interactive program based on Contextual Cognitive Behavioural Therapy.
Study NCT01221337 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: heparin free haemodialysis
Description: Comparison of two haemodialyzers VIE 2,1 versus EVODIAL 2,2 in a strategy of heparin-free haemodialysis (HFH).
Study NCT03146351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family based early intervention program (NDT-Bobath based)
Description: Family based early intervention program is NDT - Bobath based home program. Physiotherapist teaches principles of the treatment to infants' family. Family applies the program at home.
Study NCT04593797 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: carotid blood flow measurement with ultrasound
Description: carotid blood flow measurement with ultrasound vs transpulmonary thermodilution calibrated continuous cardiac output measurements
Study NCT03545984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation-based learning
Description: Simulation-based teaching involves using done on a mannequin to simulate actual conditions
Study NCT03545984 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: interactive problem based learning
Description: Standard teaching (problem based learning discussion) during cardiac/vascular rotation
Study NCT02555631 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle
Description: In this pilot study, each subject will receive the lifestyle intervention of the diabetes prevention program, a modified program for men from disadvantaged neighborhoods--a 16 weekly sessions of 1 hour each session
Study NCT03418324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105
Description: Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks
Study NCT03418324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Patients who are progressing on Abiraterone will undergo a washout period and then continue treatment with standard dosing of Abiraterone plus TRC105.
Study NCT03418324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Patients who are progressing on Enzalutamide will undergo a washout period and then continue standard treatment with Enzalutamide plus TRC105.
Study NCT04546997 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography Angiography
Description: Patients underwent non-invasive, fast, diagnostic imaging technique (optical coherence tomography angiography)
Study NCT02840994 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV301
Study NCT02840994 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study NCT02840994 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT00290706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Bortezomib 1.6mg/m2 on days 1 and 15 of each cycle, given over 3-5 seconds on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
Study NCT00290706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Gemcitabine dose of 800 mg/m2 over 30 minutes on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
Study NCT01073696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: granisetron IV
Description: IV
Study NCT01073696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granisetron patch
Description: patch
Study NCT00050349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPO906 epothilone B
Study NCT04169334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged planned program for the stay at the obstetric department
Description: A five day planned and designed program delivered to the family while at the obstetric department.
Study NCT01052168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skills training
Description: participants will train using different performance goals (based on different metrics)
Study NCT01052168 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: skills training
Description: participants will train using different performance goals (based on different metrics)
Study NCT03666260 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block
Description: Quadratus Lumborum Block with echography
Study NCT05470777 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CD22/CD19 CAR T and auto-HSCT sandwich strategy
Description: The patients received sequential infusion of CD22 and CD19 CAR-T cells (co-stimulatory molecule was 4-1BB and infusion dose was 5\*10\^6/kg respectively) after standard induction and consolidation chemotherapy. Autologous stem cells mobilization and collection were performed 6-8 weeks after CAR-T infusion. Standard BuCy as conditioning regimen for Auto-HSCT was used 4 weeks after successful stem cell collection. CD22 and CD19 CAR-T cells were re-infused 2 days after Auto-HSCT. Patients were followed up and minimal residual diseases (MRD) was monitored by flow cytometry and second-generation gene sequencing of IgH rearrangement.
Study NCT00955578 — intervention group
Intervention type: PROCEDURE
Intervention: Punch Biopsy
Description: 5-6 punch biopsies of affected areas
Study NCT03666260 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: femoral block
Description: femoral block with echography
Study NCT02255812 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Single intragastric instillation of 200 mL tap water via nasogastric tube
Study NCT02255812 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Single intragastric instillation of 2 g citric acid in 200 mL tap water via nasogastric tube
Study NCT02255812 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Single intragastric instillation of 2 g salt in 200 mL tap water via nasogastric tube
Study NCT02255812 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Single intragastric instillation of 0.017 g quinine in 200 mL tap water via nasogastric tube
Study NCT02255812 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Single intragastric instillation of 1 g monosodium glutamate in 200 mL tap water via nasogastric tube
Study NCT02255812 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Single intragastric instillation of 25 g glucose in 200 mL tap water via nasogastric tube
Study NCT03223324 — intervention group
Intervention type: DEVICE
Intervention: abdominal fetal/maternal monitor
Description: A single passive patch placed on the abdomen that incorporates 5 electrodes and a monitoring device
Study NCT03603600 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: enVista MX60E
Description: enVista MX60E monofocal IOL
Study NCT03603600 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enVista MX60EF
Description: enVista MX60EF (trifocal) multifocal IOL (MIOL)
Study NCT04258111 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI310 (anti-CTLA-4 antibody)
Description: Specified dose on specified days
Study NCT04258111 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sintilimab(anti-PD-1 antibody)
Description: Specified dose on specified days
Study NCT03766672 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Intervention Arm
Description: The intervention consists to the characterization of molecular mechanisms using to Next Generation Sequencing (NGS) technique.
Study NCT01985399 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neuropsychological testing
Description: Neuropsychological testing
Study NCT01785433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium HFA BAI 4.5 mcg
Study NCT04066738 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardiac MRI with gadolinium contrast
Description: Imaging of left ventricular scar and coronary sinus venous system
Study NCT04066738 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 3D reconstruction and location of coronary sinus venous system relative to myocardial scar
Description: Three dimensional mapping of coronary sinus venous system with Abbott Precision mapping system and Biotronik Vision wire Merge with MRI images of CS and myocardial scar
Study NCT04066738 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Acute haemodynamic measurements during CRT implant
Description: Advancement of pressure wire to LV cavity via femoral/radial arterial access. Real time measurement of LV-dP/dTmax during conventional CRT and MPP after consecutive placement of LV lead in two different CS branches (peri-infarct region and remote myocardium)
Study NCT02204618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cochlear implantation
Study NCT02204618 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 6 months initial abstention
Description: Our experimental protocol relies on real life therapeutic strategy, where a cochlear implant may be proposed once CROS and bone conductions systems have failed. Thus, all subjects enrolled in our study will try CROS and bone conduction devices. If these trials are ineffective, the remaining subjects will be randomized between two arms (cochlear implantation vs 6 months abstention followed by cochlear implantation).
Study NCT00605033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484
Description: Suboxone sublingual tablet 4 mg/1 mg - 24 mg/6 mg, daily for 28 days
Study NCT00605033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subutex, Buprenorphine Hydrochloride, SCH 28444
Description: Subutex sublingual tablet 4-24 mg, daily for 28 days
Study NCT01844544 — intervention group
Intervention type: OTHER
Intervention: inspection of medical records
Study NCT03768206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Physical Therapy
Description: Participants will receive standard outpatient physical therapy that is typical following knee replacement
Study NCT03768206 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physical Therapy
Description: Participants will receive standard outpatient physical therapy that is typical following knee replacement
Study NCT03768206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical therapist discuss aerobic physical activity
Description: Physical therapists will provide recommendations to increase aerobic physical activity and set goals during standard physical therapy sessions after knee replacement.
Study NCT03768206 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity session
Description: Participants will receive a one hour coaching session on aerobic physical activity and goal setting after knee replacement.
Study NCT03398811 — intervention group
Intervention type: DRUG
Intervention: Depot medroxy-progesterone acetate
Description: Injection every 3 months
Study NCT03398811 — intervention group
Intervention type: DRUG
Intervention: Etonogestrel
Description: 68 mg implant
Study NCT03398811 — intervention group
Intervention type: DRUG
Intervention: Desogestrel 75 µg
Description: one pill every day for 28 days without pill-free interval.
Study NCT01233154 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic
Study NCT04218669 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y Hepaticojejunostomy
Description: The common hepatic duct was cut and the duodenal side is closed by suture. The small intestine was cut off 15 cm below the ligament of Treitz. The distal end was lifted, and a 1-2 cm incision was made at the jejunal wall 4-5 cm from the jejunal stump. The anastomosis is used a 5-0 PSD Ⅱ suture, with double needles, inside-out in the jejunum and outside-in in the hepatic duct. One side of needles was used to continuely penetrate and suture the whole layer of the posterior-lateral wall of the jejunum, the posterior-lateral wall of the biliary duct, and the other side of needles was used to continuely stuere the anterior part of the anastomosis. Mucosa-to-mucosa contact should be ensured with every stitch.The anastomotic stomas were then checked for leakage. Enteric-enteric anastomosis was performed 60 cm below the site of the hepatojejunal anastomosis.
Study NCT04218669 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: T-tube drainage
Description: The T-tube was placed for biliary drainage and the common bile duct was intermittently sutured with 4-0 vicryl sutures.
Study NCT00908336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel and Erlotinib
Description: Docetaxel (Taxotere®) 75 mg/m2 iv first day of each 21-day cycle. Erlotinib (Tarceva®) 150 mg po days 2-16 of each 21-day cycle. Total: 4 cycles in the absence of disease progression
Study NCT00908336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: 150 mg/day po daily
Study NCT04251143 — intervention group
Intervention type: PROCEDURE
Intervention: corneal cross-linking
Description: UV-A Irradiation and riboflavin
Study NCT01785433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium HFA BAI 9.0 mcg
Study NCT04251143 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: corneal topography and tomography
Description: Detailed Information about corneal tomography is used for diagnosis
Study NCT04296032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: virtual reality game traning
Description: The controllers were attached to upper extremity to control the game. The game could train the shoulder, elbow, and wrist control.
Study NCT04296032 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: The program included bilateral hand, grasp/release, and pinch activities.
Study NCT02588196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone acetate
Study NCT02147587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: 5 mg twice daily of tofacitinib with background methotrexate for 12 weeks
Study NCT02147587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets twice daily with background methotrexate for 12 weeks
Study NCT02184741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB-0998
Description: Subjects received GB-0998 at 400 mg/kg body weight once daily for 5 days until 6 weeks and 6 days of gestation after confirmation of the gestational sac by ultrasonography.
Study NCT02184741 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects received the same dose of saline as GB-0998 for 5 days after confirmation of the gestational sac by ultrasonography, up to 6 weeks and 6 days of gestation.
Study NCT02401841 — intervention group
Intervention type: DRUG
Intervention: Two different types of drug for resolution of neuro-muscular blockade
Study NCT04296032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard treatment
Description: The program included bilateral hand, grasp/release, and pinch activities.
Study NCT03657238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD01
Description: single S.C. dose of RD01 for subjects in test group
Study NCT03657238 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single S.C. dose of placebo for subjects in placebo group
Study NCT02240186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microprocessor Knee (MPK)
Description: MPKs are prosthetic knees that use a microprocessor to control the prosthetic knee mechanism and adjust knee stiffness.
Study NCT02240186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Microprocessor Knee (NMPK)
Description: A NMPK is a mechanical knee with either hydraulic or pneumatic controls.
Study NCT03092596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-administered screening tool
Description: screener for drug and alcohol misuse - NIDA Quick Screen combined with AUDIT and DAST
Study NCT03092596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient health navigator-administered screening tool
Description: patient health navigator-administered screener
Study NCT03092596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient health navigator-assisted linkage to treatment
Description: patient health navigator-assisted linkage to substance abuse treatment
Study NCT01118845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SyB L-0501
Description: The administration of SyB L-0501 at 120 mg/m\^2/day by intravenous infusion on day 2 and 3 of each 21-day cycle with up to 6 cycles. Dose modifications are permitted from 2nd cycle according to dose reduction schedule.~SyB L-0501 60 mg/m\^2, 90 mg/m\^2 or 120 mg/m\^2/day on Day 2 and Day 3 will be followed by 18 days of observation.
Study NCT01118845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: The administration of rituximab at 375 mg/m\^2/day by intravenous infusion on day 1 of each 21-day cycle with up to 6 cycles. Dose modifications are not permitted.
Study NCT01341587 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Telcare Blood Glucose Meter (BGM)
Description: Cellular enabled glucometer
Study NCT01785433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPIRIVA® HandiHaler® 18 mcg/day
Study NCT06624657 — intervention group
Intervention type: OTHER
Intervention: vitamin D supplements fo 16 weks
Description: subjects exercised by HIIT-exercise for 16 weeks
Study NCT02566447 — intervention group
Intervention type: DEVICE
Intervention: Solana Trichomonas Assay Testing
Description: Specimen collection of urine and/or vaginal swabs for testing
Study NCT03857399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caspofungin
Description: Considering the possibility of fungal infection, we take empiric therapy for the patients with persistent fever and agranulocytosis using caspofungin for injection.
Study NCT03857399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caspofungin
Description: Considering the possibility of fungal infection, we take empiric therapy for the patients with persistent fever and agranulocytosis using caspofungin for injection.
Study NCT04117191 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Doctor's Best L-Tryptophan
Description: 2g tryptophan loading once